XTX Topco Ltd Buys Shares of 103,348 Verve Therapeutics, Inc. (NASDAQ:VERV)

XTX Topco Ltd purchased a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 103,348 shares of the company’s stock, valued at approximately $500,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VERV. Braidwell LP acquired a new position in Verve Therapeutics in the third quarter valued at about $3,020,000. Algert Global LLC lifted its holdings in shares of Verve Therapeutics by 63.1% in the 3rd quarter. Algert Global LLC now owns 224,216 shares of the company’s stock worth $1,085,000 after acquiring an additional 86,720 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Verve Therapeutics by 138.1% during the 2nd quarter. Renaissance Technologies LLC now owns 474,500 shares of the company’s stock worth $2,316,000 after purchasing an additional 275,173 shares during the period. FMR LLC boosted its position in shares of Verve Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after purchasing an additional 3,873 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Verve Therapeutics by 28.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,366 shares of the company’s stock valued at $337,000 after purchasing an additional 5,600 shares during the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.

Verve Therapeutics Stock Down 8.3 %

NASDAQ:VERV opened at $5.71 on Friday. Verve Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $19.34. The company has a fifty day simple moving average of $5.71 and a two-hundred day simple moving average of $5.65. The company has a market cap of $483.41 million, a price-to-earnings ratio of -2.32 and a beta of 1.71.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm had revenue of $6.87 million during the quarter, compared to analyst estimates of $2.75 million. During the same period last year, the business posted ($0.72) earnings per share. Verve Therapeutics’s revenue was up 120.2% compared to the same quarter last year. On average, analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on VERV shares. HC Wainwright lowered their price target on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada decreased their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.